Global Healthcare Embraces Early Cancer Screening: Completion of $20 Billion Mega Deal

On March 23, Abbott Laboratories (NYSE: ABT) completed its acquisition of early cancer-detection and precision oncology-diagnostics firm Exact Sciences, making it a wholly owned subsidiary and adding flagship products such as Cologuard and Oncotype DX to its portfolio. With this transaction, Abbott strengthens its position in the U.S. cancer-screening and precision-oncology diagnostics market, securing a new growth driver alongside its existing high-single-digit growth trajectory. As of March 20, Exact Sciences common stock ceased trading on Nasdaq. Concurrently, Abbott filed a legal opinion confirming the validity and enforceability of $20 billion in aggregate principal amount of senior unsecured notes, issued in eight tranches maturing between 2029 and 2066.

According to market disclosures, under a February 23 agreement with a syndicate led by Morgan Stanley, Barclays, Bank of America and JPMorgan, Abbott has set interest rates on the $20 billion multi-tranche offering. Proceeds will fund the Exact Sciences acquisition, repay certain indebtedness and support general corporate purposes. In late February, Abbott’s fourth-quarter results showed revenues slightly below consensus and conservative near-term guidance, driving increased share-price volatility.

Headquartered in Abbott Park, Illinois, Abbott is a global healthcare company marketing products in over 160 countries across four segments: medical devices, diagnostics, nutrition and established pharmaceuticals. The Exact Sciences acquisition expands Abbott’s footprint in the high-growth diagnostics arena of early cancer detection and precision oncology, further intensifying competition in the global cancer-screening and precision-medicine market.